ABSTRACT Between 1969 and 1979, 90 patients of the Thoracic Surgical Unit at Harefield Hospital were found to have pulmonary metastatic disease. In 25 instances (28 %) the diagnosis was established by bronchial biopsy. Twenty-four patients had endobronchial metastatic carcinoma and in one metastatic sarcoma was diagnosed. All but one had a past history of malignancy, the interval between treatment of the primary and appearance of the endobronchial metastasis ranging from a few months to 17 years. Primary sites in these patients included large intestine, breast, cervix, uterus, and bladder. There were four instances of metastatic malignant melanoma. The pulmonary secondaries were resectable in 10 patients and in one a second resection was done for a further metastasis three years after the first. Three patients are still alive two, four, and 10 years later.
It is reported that the incidence of endobronchial metastatic disease is about 2 %.1 This figure was reached by a review of postmortem findings. In the present series of 90 surgical patients with pulmonary metastases, 28 % had endobronchial tumour. All the lesions were readily visible bronchoscopically, involving bronchi proximal to subsegmental level. These findings suggest that the incidence of bronchial involvement by pulmonary secondaries is greater than generally supposed and that bronchoscopy should form an essential part of the investigation and assessment of such patients, whether the diagnosis is suspected or not. The other two patients died of their disease after two and nine months.
Methods
Metastatic transitional cell carcinoma caused the death of one of two patients four months after diagnosis of the pulmonary lesion. The other survived resection of one metastasis only to succumb 36 months later from postoperative pulmonary embolus after residual pneumonectomy for a second metastasis which had also been diagnosed by bronchial biopsy.
All the patients with metastatic malignant melanoma died within a year of diagnosis as did three of the four patients with metastases from intraduct or spheroidal cell carcinoma of breast. The fourth lived for 44 months. One patient with an endobronchial lesion from a leiomyosarcoma of the uterus died of recurrence 22 months later.
Of the three patients still alive, two had adenocarcinoma. They are well after four and 10 years. In four patients the interval was five to nine years. Two with breast primaries died six and eight months after diagnosis of the endobronchial metastasis. One who had a metastasis from a carcinoma of the cervix died after 32 months from non-malignant causes. One is alive and well 10 years after resection of a metastasis from the large intestine.
In four patients the interval was 10 or more years. Two with malignant melanoma lived for only four and nine months and one with metastatic breast carcinoma for only three months. One patient who developed a bladder metastasis underwent lobectomy and three years later developed a further secondary. This was also resected but the patient died postoperatively from a pulmonary embolus. 
